Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor
agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the
treatment of subjects who are overweight or obese.